Filneon contains Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF). It is used to stimulate the production of neutrophils, a type of white blood cell crucial for fighting infections, particularly in patients undergoing chemotherapy.
Uses
- Reducing the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
- Treating neutropenia caused by bone marrow transplantation or other conditions.
- Mobilization of peripheral blood progenitor cells (PBPCs) for collection and autologous transplantation.
- Increasing neutrophil counts in patients with severe chronic neutropenia (SCN).
Filgrastim binds to and stimulates the G-CSF receptors on the surface of precursor cells in the bone marrow, leading to increased production, maturation, and release of neutrophils into the bloodstream.
Onset of Action - 24 to 48 hours after administration.
Duration of Action - The effect persists for about 1 to 2 weeks after the last dose.
Dosage
- Chemotherapy-induced Neutropenia: 5 mcg/kg/day subcutaneously or intravenously, starting at least 24 hours after chemotherapy.
- PBPC Mobilization: 10 mcg/kg/day subcutaneously.
- Severe Chronic Neutropenia: 6 mcg/kg/day (congenital) or 5 mcg/kg/day (cyclic).
Common Side Effects
- Bone pain
- Nausea
- Fatigue
- Headache
- Injection site reactions
Precautions
- Monitor white blood cell (WBC) counts to prevent leukocytosis.
- Use cautiously in patients with a history of splenomegaly or sickle cell disease.
Drug Interactions
- Avoid combining with lithium due to potential additive effects on neutrophil proliferation.
- Caution when used alongside antineoplastic agents as Filgrastim may alter their efficacy.
Storage
- Store between 2°C to 8°C. Avoid freezing. Protect from light.
X
Download App
